Status:
COMPLETED
PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome
Lead Sponsor:
University Medical Centre Ljubljana
Conditions:
PCOS
Obesity
Eligibility:
FEMALE
18-55 years
Phase:
PHASE4
Brief Summary
The purpose of this study was to determine whether monotherapy treatment with phosphodiesterase-4 (PDE-4) inhibitor roflumilast is more effective than treatment with glucagon-like protein 1 (GLP-1) li...
Eligibility Criteria
Inclusion
- 18 years old to menopause
- polycystic ovary syndrome (NICHD criteria)
- BMI of 30 kg/m² or higher
Exclusion
- depression
- type 1 or type 2 diabetes mellitus
- history of carcinoma
- history of pancreatitis
- Cushing's syndrome or congenital (non-classic) adrenal hyperplasia
- significant cardiovascular, kidney or hepatic disease
- the use of medications other than metformin known or suspected to affect reproductive or metabolic functions
- the use of statins, within 90 days prior to study entry
Key Trial Info
Start Date :
March 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT02187250
Start Date
March 1 2014
End Date
June 1 2014
Last Update
July 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Ljubljana
Ljubljana, Slovenia, 1000